• PTT and CD47 Blockade Synergy: Calreticulin and ECM Remodeli

  2026-06-05

  This study demonstrates that combining photothermal therapy (PTT) with CD47 immune checkpoint blockade markedly enhances macrophage-mediated clearance of oral squamous cell carcinoma (OSCC). By inducing calreticulin exposure and remodeling the tumor extracellular matrix, this combination overcomes key barriers to effective immunotherapy and provides a new mechanistic framework for improving solid tumor responses.

• Tin Mesoporphyrin IX (chloride): Heme Oxygenase Inhibition i

  2026-06-05

  Tin Mesoporphyrin IX (chloride) is a potent, nanomolar-affinity inhibitor of heme oxygenase, widely used in metabolic disease and virology research. Its high specificity and reproducibility make it a standard tool for dissecting heme catabolism and related signaling pathways.

• SCUBE3 Antibody Targeting: Suppressing Oncogenic and Immune

  2026-06-04

  The reference study identifies secretory SCUBE3 as a critical driver of tumor progression, therapy resistance, and immune evasion by orchestrating oncogenic signaling and modifying the tumor microenvironment. Using a first-in-class neutralizing antibody, the research demonstrates effective inhibition of tumor growth and restoration of antitumor immunity, providing a promising direction for pan-cancer therapeutic strategies.

• Chenodeoxycholic Acid in FXR Signaling and Renal Protection

  2026-06-04

  Chenodeoxycholic Acid (CDCA) is redefining cholesterol metabolism and nuclear receptor signaling research with its robust FXR agonism. Recent studies reveal its power in translational renal models, positioning CDCA as a frontrunner for mechanistic exploration and prophylactic strategy development, especially in acute kidney injury workflows.

• Z-VDVAD-FMK: Irreversible Caspase-2 Inhibition for Apoptosis

  2026-06-03

  Z-VDVAD-FMK is a potent, irreversible, cell-permeable inhibitor targeting caspase-2 and is widely used in apoptosis research. Its covalent binding mechanism enables robust inhibition of caspase-mediated cell death pathways, facilitating the dissection of mitochondrial and caspase-dependent events. This article details its validated applications, mechanistic specificity, and practical integration into apoptosis assays.

• Degarelix Acetate: Rapid Androgen Deprivation in Prostate Ca

  2026-06-03

  This review highlights the clinical innovation of degarelix acetate, a third-generation GnRH antagonist, which enables rapid and sustained androgen deprivation in prostate cancer without the testosterone surge associated with GnRH agonists. Its distinct pharmacological profile improves both efficacy and safety, informing advanced therapeutic strategies and future cross-domain research.

• Cell Surface Integrity Sets Ploidy Limits in Budding Yeast

  2026-06-02

  This study demonstrates that the maximum ploidy in Saccharomyces cerevisiae is constrained by cell surface integrity, rather than solely by DNA replication capacity. The findings reveal that alleviating cell surface stress allows yeast cells to tolerate higher ploidy, with notable implications for understanding genome duplication, cell size, and antifungal drug mechanisms.

• Cinoxacin In Vitro: Antibacterial Spectrum and Resistance Dy

  2026-06-02

  The landmark 1975 study by Lumish and Norden established Cinoxacin’s in vitro activity against a broad range of gram-negative aerobic bacteria, using rigorous MIC and bactericidal assays. Their findings not only defined Cinoxacin’s spectrum but also highlighted resistance development and methodological standards that shape urinary tract infection and antimicrobial resistance research today.

• FXR-KLF11 Axis: CDCA Attenuates CI-AKI via JAK2/STAT3 Suppre

  2026-06-01

  This study provides mechanistic evidence that Chenodeoxycholic Acid (CDCA) protects against contrast-induced acute kidney injury (CI-AKI) by activating FXR, which upregulates KLF11 and suppresses JAK2/STAT3 signaling. These findings clarify a renal protective pathway and inform future research on nuclear receptor-based prophylactics.

• AI-Guided Discovery of Senolytics: New Directions for EGFR/E

  2026-06-01

  The referenced study demonstrates a machine learning-driven approach to identify novel senolytic compounds, significantly reducing screening costs and expanding opportunities for targeting cellular senescence. These advances may inform future therapeutic strategies in cancer and age-related disease, including research involving EGFR and ErbB2 inhibition.

• Mitochondrial Antioxidant SkQ1 Fails to Prevent Muscle Atrop

  2026-05-31

  This study demonstrates that the mitochondrial-targeted antioxidant SkQ1 effectively suppresses mitochondrial apoptotic signaling in skeletal muscle during ovarian cancer but does not prevent muscle atrophy. The findings challenge the presumed causal role of mitochondrial apoptosis and necroptosis in cancer-associated muscle wasting, highlighting the complexity of underlying mechanisms.

• Syringin Natural Product: Mechanism, Evidence, and Research

  2026-05-30

  Syringin is a bioactive natural product with validated anticancer activity via modulation of the EGFR/PI3K/Akt pathway. Recent research demonstrates its role in enhancing sunitinib efficacy in renal cell carcinoma cells and inhibiting tumor cell proliferation. These properties make Syringin a valuable tool for bioactive compound screening and signaling pathway research.

• Chenodeoxycholic Acid: FXR-KLF11 Pathway in Translational Re

  2026-05-29

  This article provides advanced mechanistic insights and strategic guidance for translational researchers leveraging Chenodeoxycholic Acid (CDCA) in the study of FXR-mediated nuclear receptor signaling and renal protection. By dissecting the FXR-KLF11-JAK2/STAT3 axis, it bridges molecular understanding with actionable protocols, highlights recent breakthroughs in contrast-induced acute kidney injury (CI-AKI) models, and offers a forward-looking perspective on integrating CDCA into high-impact metabolic and kidney injury research.

• Cardiogreen (Indocyanine Green): Advanced Protocols & PDT Sy

  2026-05-29

  Cardiogreen (Indocyanine Green) empowers high-sensitivity vascular imaging and next-generation photodynamic therapy with robust, reproducible workflows. This article delivers stepwise protocol enhancements, troubleshooting tactics, and practical insights that bridge gold-standard diagnostics with emerging immuno-oncology strategies.

• Wnt Agonist 1 (BML-284): Reliable Wnt Pathway Activation Wor

  2026-05-28

  Wnt agonist 1 (BML-284) from APExBIO empowers reproducible Wnt signaling pathway activation, crucial for dissecting cellular differentiation and chemoresistance in cutting-edge models. This guide demystifies experimental setup, practical protocol parameters, and advanced troubleshooting to maximize confidence in developmental and cancer biology research.

16667 records 1/1112 page Next 12345 下5页 Last page